What Makes Supernus (SUPN) a New Buy Stock

Core Viewpoint - Supernus Pharmaceuticals (SUPN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook driven by an upward trend in earnings estimates [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which significantly influence stock price movements [4][6]. - Rising earnings estimates for Supernus suggest an improvement in the company's underlying business, likely leading to higher stock prices [5]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Supernus's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions for Supernus - For the fiscal year ending December 2025, Supernus is expected to earn $2.06 per share, reflecting a year-over-year decline of -34.4% [8]. - Over the past three months, the Zacks Consensus Estimate for Supernus has increased by 12.4%, indicating positive revisions from analysts [8].